Monitor the SITC presentation on Nov 4-8 for any preclinical efficacy or safety data that could inform the IND timeline for Aptevo's multispecific candidates. The filing itself contains no new binary catalyst — the presentation is a routine scientific update.
Price Chart
Executive Summary
Aptevo announced a non-clinical scientific presentation of its multispecific CD40-directed platform at the SITC 2026 Annual Meeting (Nov 4-8). The presentation (Abstract #1060) covers preclinical data on tumor-localized CD40 agonism designed to coordinate innate and adaptive immunity. No clinical data, financial figures, or regulatory milestones were disclosed.
Key Facts
- Presentation at SITC 2026 Annual Meeting, November 4-8, 2026 in Phoenix, AZ
- Abstract #1060: 'Leveraging multispecific antibody-like molecules to localize CD40 agonism to the tumor to overcome the immunosuppressive microenvironment and potentiate anti-tumor immunity'
- Presenter: Michelle Nelson, PhD, et al.
- Platform technology combines tumor targeting with localized CD40 and T cell activation
- No clinical data, financial results, or regulatory updates provided
Financial Impact
No financial impact disclosed; pre-clinical platform presentation with no revenue or cost figures
Risk Factors
- No clinical data disclosed; platform remains preclinical
- No timeline for IND submission or next clinical milestone provided
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-421076 |
| Document: apvo-ex99_1.htm | 0001193125-26-421076 |
| Document: 0001193125-26-421076-index-headers.html | 0001193125-26-421076 |
| Document: 0001193125-26-421076-index.html | 0001193125-26-421076 |
| Document: 0001193125-26-421076.txt | 0001193125-26-421076 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $1.73 | awaiting T+5 | — | $1.73 (−0.10%) |
Oct 23, 2026 2d ago | 8-K | $1.61 | awaiting T+5 | — | $1.73 (+7.45%) |
Oct 14, 2026 12d ago | 8-K | $1.73 $1.60 | ▼ −7.51% | ▼ −7.97% | $1.73 (+0.00%) |
Sep 24, 2026 4w ago | 8-K | $1.83 $1.76 | ▼ −3.83% | ▼ −3.41% | $1.73 (−5.46%) |
Sep 3, 2026 7w ago | 424B4 / 8-K | $1.71 $1.82 | ▲ +6.43% | ▲ +7.58% | $1.73 (+1.17%) |
Sep 3, 2026 7w ago | EFFECT | $1.71 $1.82 | ▼ −6.43% | ▼ −7.58% | $1.73 (−1.17%) |
Aug 14, 2026 10w ago | 8-K | $2.94 $2.68 | ▼ −8.84% | ▼ −7.48% | $1.73 (−41.16%) |
Jul 27, 2026 12w ago | 8-K | $4.21 $3.95 | ▼ −6.18% | ▼ −8.44% | $1.73 (−58.91%) |
Jun 30, 2026 16w ago | 8-K | $4.45 $4.51 | ▲ +1.35% | ▲ +1.09% | $1.73 (−61.12%) |
May 6, 2026 24w ago | 8-K | $4.86 $4.76 | ▼ −2.06% | ▼ −3.56% | $1.73 (−64.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers